BSEM · BioStem Technologies, Inc.
$2.45
-0.31 (-11.07%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, substantial doubt exists about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$68.36M
Shares
17.85M
Volume · Oct 6
128.6K
Avg daily vol (3M)
117.04K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.76
Open$2.74
Day$2.58–2.83
52W close$2.73–8.20
Avg vol 30d158K
Short int134K · 0.8% float · 1.0d
Short vol49%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Oct 22, 2026
Est · unconfirmed
· in 2 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$34.59M
Trailing 12 months
Net income (TTM)
−$28.29M
Trailing 12 months
Revenue growth YoY
-27.9%
Year over year
Operating margin
-67.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-12.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$6.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-26.0%
Year over year · fewer shares
Price change (1Y)
-45.9%
Trailing year
Short interest
0.8%
Latest settlement · 1.0 days to cover
AI Brief
Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26
TL;DR. BioStem reported Q2 revenue of $7.9 million, up 29% sequentially, driven by hospital channel growth, raised full-year 2026 revenue guidance to $26–29 million from $25–29 million, and completed its uplisting to Nasdaq; however, GAAP net loss widened to $9.0 million, Adjusted EBITDA swung to a $4.6 million loss, and the company expects gross margin pressure in the second half.
Bullish
- + Q2 revenue grew 29% sequentially to $7.9 million, with hospital revenue rising to $6.7 million from $5.4 million.
- + Raised full-year 2026 revenue guidance to $26–29 million from prior $25–29 million.
- + Completed uplisting to Nasdaq Capital Market on August 7, 2026.
- + Manufacturing transfer expected to add 15–20 points of gross margin once NEOX/Clerix production moves in-house.
- + Sales force expansion on track to reach more than 40 W-2 reps and 30 independent agents by year-end, more than doubling since acquisition.
Bearish
- − GAAP net loss widened to $9.0 million (loss of $0.52/share) versus net income of $10,613 in Q2 2025.
- − Adjusted EBITDA swung to a loss of $4.6 million from income of $2.5 million in Q2 2025.
- − Q2 revenue of $7.9 million declined versus $11.0 million in Q2 2025 and gross margin compressed to 61% from 94% a year earlier.
- − Company expects modest gross margin pressure in the second half of 2026 as it works through discounted acquisition inventory.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
−25%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−43%
trailing
YTD return
−28%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.75% of float · ▲ +12.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
31
low risk · 0–100
Fundamentals
Revenue growth
−32%
Y/Y
Gross margin
94%
expanding
EPS growth
−127%
Y/Y
Free cash flow
$6.6M
Balance sheet
$29.5M
net cash
Quant / Vol
risk profile
Volatility
117%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
16.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 12, 2026
Revenue
· full year 2026
Raised
$26M – $29M
May 14, 2026
$25M – $29M
changed to
Aug 12, 2026
$26M – $29M
prior FY $47.48M
midpoint −42.1% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.75% of float · ▲ +12.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $3
Now $3 · 0%
Range high $8
vs 200-day avg -38%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$4.6M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA -$8,305,405
+$2,363,577 Share-based compensation
-$815,250 Gain on extinguishment of debt
+$1,412,000 Fair value adjustment on contingent consideration
+$722,011 Transaction related costs
= Adjusted EBITDA -$4,623,067
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BSEM
this stock
BioStem Technologies, Inc.
|
$68.36M | -27.7% | -31.8% | — | 0.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BSEM | -32.0% | -25.7% | -43.3% | -10.8% | -27.7% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -33.2% | -26.3% | -54.9% | -12.4% | -41.3% |